Therefore, the addition of serplulimab to chemotherapy is not an economical choice for advanced ESCC patients with PD-L1-positive, PD-L1 1≤ CPS< 10 and CPS ≥ 10 in China. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.